DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for GM1 gangliosidosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGM1 gangliosidosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gm1 gangliosidosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
galactosidase beta 1 (GLB1) — GLB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2r,3s,4r,5sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3THD · 1.79 Å · ligand (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol (DGJ). Experimental structure, not a prediction.
What the evidence adds up to
A 2022 retrospective study of 14 patients followed at a single Turkish centre between 1988 and 2021 found that median survival in GM1 gangliosidosis is less than 24 months. Beta-galactosidase enzyme activity may be associated with clinical onset and time of diagnosis. The study did not report any therapeutic intervention or outcome data beyond survival.
A 2024 review describes several approaches under investigation for GM1 gangliosidosis: enzyme replacement therapy, substrate reduction therapy, stem cell therapy, and gene editing. The review states that effectiveness is limited for neuropathic GM1 because the blood–brain barrier restricts delivery to the brain. Enzyme replacement and substrate reduction require lifelong exogenous supplementation, while gene editing could be curative by fixing the GLB1 gene to enable endogenous enzyme activity. Stem cell therapy can combine ex vivo gene editing of cells to produce enzyme. A few therapeutic interventions have progressed to early-phase clinical trials, but the review gives no specific results from those trials — no response rates, no survival data, no enzyme activity levels in patients.
A 1996 study cloned a partial canine beta-galactosidase cDNA with 86% identity to the human gene and found conservation of exon number and size. Northern blotting showed a single mRNA of 2.4 kb in fibroblasts and liver from both normal dogs and dogs affected with GM1 gangliosidosis. The authors concluded that canine GM1 gangliosidosis is a suitable animal model for developing a gene therapy strategy, but no therapeutic results in dogs were reported.
What is still missing: no completed controlled trials have shown that any intervention improves survival or neurological outcomes in patients with GM1 gangliosidosis. The 2024 review mentions early-phase trials but provides no efficacy data. The 2022 study gives a median survival of less than 24 months but does not test any treatment. Money for adequately powered trials, strategies to overcome the blood–brain barrier in humans, and patient stratification by residual enzyme activity remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Neuroscience · 2024 · 18 citations · open access
Therapeutic developments for neurodegenerative GM1 gangliosidosis
AbstractGM1 gangliosidosis (GM1) is a rare but fatal neurodegenerative disease caused by dysfunction or lack of production of lysosomal enzyme, β-galactosidase, leading to accumulation of substrates. The most promising treatments for GM1, include enzyme replacement therapy (ERT), substrate reduction therapy (SRT), stem cell therapy and gene editing. However, effectiveness is limited for neuropathic GM1 due to the restrictive nature of the blood–brain barrier (BBB). ERT and SRT alleviate substrate accumulation through exogenous supplementation over the patient’s lifetime, while gene editing could be curative, fixing the causative gene, GLB1 , to enable endogenous enzyme activity. Stem cell therapy can be a combination of both, with ex vivo gene editing of cells to cause the production of enzymes. These approaches require special considerations for brain delivery, which has led to novel formulations. A few therapeutic interventions have progressed to early-phase clinical trials, presenting a bright outlook for improved clinical management for GM1.
American Journal of Medical Genetics · 1996 · 6 citations
Comparison of the canine and human acid β-galactosidase gene
AbstractSeveral canine cDNA libraries were screened with human beta-galactosidase cDNA as probe. Seven positive clones were isolated and sequenced yielding a partial (2060 bp) canine beta-galactosidase cDNA with 86% identity to the human beta-galactosidase cDNA. Preliminary analysis of a canine genomic library indicated conservation of exon number and size. Analysis by Northern blotting disclosed a single mRNA of 2.4 kb in fibroblasts and liver from normal dogs and dogs affected with GM1 gangliosidosis. Although incomplete, these results indicate canine GM1 gangliosidosis is a suitable animal model of the human disease and should further efforts to devise a gene therapy strategy for its treatment.
Balkan Medical Journal · 2022 · 2 citations · open access
Single Institutional Experience with GM1 Gangliosidosis: Clinical and Laboratory Results of 14 Patients
AbstractBackground: gene. Neurodegeneration, hypotonia, visceromegaly, macular cherry-red spots, skeletal dysplasia, and coarse and dysmorphic face are the major clinical features. Aims: To evaluate the demographic and clinical data of patients with GM1 gangliosidosis in a single center. Study Design: A retrospective clinical study. Methods: This study included patients followed at Hacettepe University İhsan Doğramacı Children’s Hospital Pediatric Metabolism Unit with the diagnosis of GM1 gangliosidosis between 1988 and 2021. Hospital records of the patients were reviewed for demographic, clinical, and laboratory findings. Results: < 0.05). Conclusion: Median survival in patients with GM1 gangliosidosis is less than 24 months. Beta-galactosidase enzyme activity may be associated with clinical onset and time of diagnosis in these patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
